Description
The innate mechanisms that control sleep have fascinated scientists for generations, and many different
endogenous compounds have been proposed as sleep controllers over the years.
Delta sleep inducing peptide (DSIP), a nonapeptide with a unique amino acid sequence found
naturally(!), which was isolated in the 1980s in Russia, of course. To date, studies are underway o
The potential benefits of this peptide.
As for the literature, the bibliography regarding DSIP can be estimated at no less than 1,500
literature items. The aforementioned studies (bibliography) have shown that DSIP occurs both
In both free and bound forms in certain brain structures, primarily in the
The hypothalamus and limbic system, as well as the pituitary gland and various organs
Peripheral organs, tissues and body fluids.
DSIP is usually present in the blood in small amounts. DSIP concentrations in brain and plasma
show marked diurnal variability, and it has been shown that there is a correlation between DSIP concentrations in the
plasma versus diurnal rhythms in humans. Concentrations are low in the morning and higher in the afternoon. It has been shown that
Increased endogenous DSIP levels are associated with inhibition of both sleep
slow-wave sleep, as well as sleep with rapid eye movements and, interestingly, also with temperature
bodies.
The potential benefits of DSIP go far beyond improving sleep….
– The first important thing about DSIP is that it doesn’t actually induce sleep despite the
misleading name. It has been shown to improve deep sleep phases. Studies show that
DSIP helps normalize sleep and regulate dysfunction in sleep cycles.
– One study showed that DSIP inhibits somatostatin, a protein produced in cells
muscle, which inhibits muscle growth. DSIP has also been shown to release growth hormone in the
As a result of the hypothalamus and pituitary gland. It has also been shown to increase LH levels.
-Preclinical studies in humans have shown that DSIP can significantly reduce the sensation of
pain and improve mood. DSIP acts on central opioid receptors to produce the effect of
analgesic.
– DSIP limits changes in levels of type A monoamine oxidase and serotonin. Also, the analysis
Cerebrospinal fluid of patients suffering from Severe Depression indicates a decrease in the
level.
– DSIP was tested for its ability to reduce withdrawal symptoms during detoxification
From opiates and alcohol. Study on 107 patients showed TOTAL resolution of symptoms
withdrawal or significant improvement.
– DSIP has also been studied for cancer , as well as supportive treatment. Treated
Rats showed a 2.6-fold reduction in tumor growth.
All products listed on this website (LunaPharm.eu) are for research purposes only. Luna Pharm does not encourage or promote the use of any of these products for personal use (i.e., human consumption), or products intended for use as a drug, stimulant or for use in any food product.
